You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MSIS-29

Showing 1 - 25 of 1,071
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Primary Progressive Trial in Kaposvár (Training groupe, PNF,

Completed
  • Multiple Sclerosis, Chronic Progressive
  • Multiple Sclerosis, Primary Progressive
  • Training groupe
  • +3 more
  • Kaposvár, Somogy, Hungary
    Somogy Megyei Kaposi Mór Oktató Kórház
Mar 24, 2022

MS Patients Treated With Sphingosine-1-phosphate Receptor

Recruiting
  • Multiple Sclerosis
  • S1PR analysis on immune cells
  • Bern, Switzerland
    Neurology department
Apr 12, 2023

Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS Trial in Amsterdam

Recruiting
  • Multiple Sclerosis
  • +5 more
  • Amsterdam, Netherlands
    Amsterdam UMC, location VUmc
Apr 17, 2023

Ofatumumab in Portuguese Multiple Sclerosis Patients

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • (no location specified)
Mar 30, 2023

WOE of Anti-CD20 Therapies

Not yet recruiting
  • Multiple Sclerosis
  • (no location specified)
Oct 31, 2023

Multiple Sclerosis, Epilepsy, Parkinson Disease Trial in Pozzilli (Psychometric Evaluations)

Enrolling by invitation
  • Multiple Sclerosis
  • +4 more
  • Psychometric Evaluations
  • Pozzilli, Isernia, Italy
    Ircss Neuromed
Dec 19, 2022

Multiple Sclerosis, Insomnia Trial in Uppsala (i-CBT, Applied relaxation)

Not yet recruiting
  • Multiple Sclerosis
  • Insomnia
  • i-CBT
  • Applied relaxation
  • Uppsala, Uppland, Sweden
    Department of Psychology, Uppsala University
Sep 1, 2023

Multiple Sclerosis Trial in Saint Petersburg (Fludarabine Phosphate for Injection)

Recruiting
  • Multiple Sclerosis
  • Fludarabine Phosphate for Injection
  • Saint Petersburg, Russian Federation
    First Pavlov State Medical University of St. Petersburg
Apr 14, 2023

Transitioning Patients From Natalizumab to Ocrelizumab

Completed
  • Relapsing Remitting Multiple Sclerosis
    • Livingston, New Jersey
    • +4 more
    Feb 2, 2022

    Kesimpta® in Swiss Multiple Sclerosis Patients -Observational

    Recruiting
    • Multiple Sclerosis
    • Ofatumumab
    • Baden, Aargau, Switzerland
    • +17 more
    Jan 20, 2023

    Relapsing Remitting Multiple Sclerosis Trial in Portland (3 mg Melatonin, 5 mg Melatonin)

    Active, not recruiting
    • Relapsing Remitting Multiple Sclerosis
    • 3 mg Melatonin
    • 5 mg Melatonin
    • Portland, Oregon
      Providence MS Center
    May 5, 2022

    Multiple Sclerosis Trial in Bordeaux (DigiCog (BCCAMS app), Konectom Application)

    Completed
    • Multiple Sclerosis
    • DigiCog (BCCAMS app)
    • Konectom Application
    • Bordeaux, France
      Research Site
    Sep 21, 2022

    Pediatric Onset Multiple Sclerosis (POMS) Trial in Houston (VR active video game intervention, Educational session, Standard

    Terminated
    Has Results
    • Pediatric Onset Multiple Sclerosis (POMS)
    • VR active video game intervention
    • +2 more
    • Houston, Texas
      The University of Texas Health Science Center,Houston
    May 17, 2022

    Multiple Sclerosis Trial in Littleton (Neubie)

    Completed
    • Multiple Sclerosis
    • Neubie
    • Littleton, Colorado
      Centura Health at Home
    Aug 10, 2022

    Kesimpta® Treatment Effects in Relapsing Multiple Sclerosis

    Recruiting
    • Multiple Sclerosis
    • Ofatumumab
    • Bamberg, Bavaria, Germany
    • +21 more
    Jan 25, 2023

    Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive Trial in Cleveland (Cionic

    Recruiting
    • Multiple Sclerosis
    • +2 more
    • Cionic Neural Sleeve NS-100
    • Actigraph accelerometer
    • Cleveland, Ohio
      Cleveland State University
    Jul 25, 2023

    Multiple Sclerosis Trial (Frexalimab, Placebo, MRI contrast-enhancing agents)

    Not yet recruiting
    • Multiple Sclerosis
    • (no location specified)
    Nov 15, 2023

    Tysabri in Early Relapsing Remitting Multiple Sclerosis

    Active, not recruiting
    • Relapsing Remitting Multiple Sclerosis
    • Amadora, Portugal
    • +17 more
    Apr 12, 2022

    Multiple Sclerosis Trial in Worldwide (SAR443820, Placebo)

    Recruiting
    • Multiple Sclerosis
    • Bruxelles, Belgium
    • +16 more
    Jan 31, 2023

    Multiple Sclerosis Trial in Saskatoon (Individualized behavioural physical activity intervention)

    Completed
    • Multiple Sclerosis
    • Individualized behavioural physical activity intervention
    • Saskatoon, Saskatchewan, Canada
      University of Saskatchewan
    Nov 28, 2021

    Multiple Sclerosis, Spasticity, Muscle, Pain Trial in Bergen (FlowOx 2.0)

    Enrolling by invitation
    • Multiple Sclerosis
    • +2 more
    • FlowOx 2.0
    • Bergen, Norway
      Dept. of Neurology Haukeland Univ. Hospital & Dept. of Clin. Med
    Jan 20, 2023

    Multiple Sclerosis Trial in Portland (ADSTEP)

    Active, not recruiting
    • Multiple Sclerosis
    • ADSTEP
    • Portland, Oregon
      Oregon Health and Science University
    Nov 7, 2022

    Multiple Sclerosis Trial in Worldwide (MSCopilot® mobile application)

    Not yet recruiting
    • Multiple Sclerosis
    • MSCopilot® mobile application
    • Oklahoma City, Oklahoma
    • +6 more
    Apr 3, 2023

    Multiple Sclerosis, Relapsing-Remitting, Fatigue Trial (TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY], Placebo)

    Withdrawn
    • Multiple Sclerosis, Relapsing-Remitting
    • Fatigue
    • TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]
    • Placebo
    • Boston, Massachusetts
      Massachusetts General Hospital
    Nov 14, 2022

    Falls, Motor Imagery, Multiple Sclerosis Trial in Orangeburg (Motor Imagery as compared to physical practice for balance tasks)

    Not yet recruiting
    • Falls
    • +4 more
    • Motor Imagery as compared to physical practice for balance tasks
    • Orangeburg, New York
      Dominican University New York
    Nov 7, 2022